SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Eloranta S)
 

Sökning: WFRF:(Eloranta S) > Long-term survival ...

  • Ekberg, S.Karolinska Institute,Karolinska Institutet,Karolinska University Hospital (författare)

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

  • Artikel/kapitelEngelska2018

Förlag, utgivningsår, omfång ...

  • 2018-06-20
  • Wiley,2018

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/271944
  • https://gup.ub.gu.se/publication/271944URI
  • https://doi.org/10.1002/ajh.25147DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-362700URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:138943734URI
  • https://lup.lub.lu.se/record/376b4c2f-e0a5-4db2-83d3-13f9bff41747URI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of anti-CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population-based level. Patients diagnosed with DLBCL 2000-2013 (N=7114) were identified through the Swedish Lymphoma Registry and classified according to the age-adjusted International Prognostic Index (aaIPI). The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2-year survivors, by age and sex. Median age at DLBCL-diagnosis was 70 (18-105) years and 54.8% presented with stage III-IV disease. On average, LEL due to DLBCL decreased from 8.0 (95% CI: 7.7-8.3) to 4.6 (95% CI: 4.5-4.6) years over the study period. By risk group, LEL was most reduced among patients with aaIPI >= 2 aged 50-60 years. However, these patients were still estimated to lose >8 years in 2013 (eg, LELmales50years 8.6 years (95% CI: 5.0-12.3)). Among 2-year survivors, LEL was reduced from 6.1 years (95% CI: 5.6-6.5) (aaIPI >= 2) and 3.8 years (95% CI: 3.6-4.1) (aaIPI<2) to 1.1 (95% CI: 1.1-1.2) and 1.0 year (95% CI: 0.8-1.1), respectively. The reduction was observed across all ages. Results for females were similar. By using LEL we illustrate the improvement of DLBCL survival over time. Despite adequate immunochemotherapy, substantial LEL among patients with IPI >= 2 points to remaining unmet medical needs. We speculate that observed reduced losses among 2-year survivors indicate a reduction of late relapses.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Jerkeman, MatsLund University,Lunds universitet,Lymfom - Klinisk forskning,Forskargrupper vid Lunds universitet,Lymphoma - Clinical Research,Lund University Research Groups(Swepub:lu)onk-mje (författare)
  • Andersson, Per-Ola,1964University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine,Gothenburg Univ, Boras & Sahlgrenska Acad, South Alvsborg Hosp, Dept Hematol, Gothenburg, Sweden(Swepub:gu)xapert (författare)
  • Enblad, GunillaUppsala universitet,Experimentell och klinisk onkologi,Uppsala University Hospital(Swepub:uu)gunienbl (författare)
  • Wahlin, B. E.Karolinska Institute,Karolinska Institutet (författare)
  • Hasselblom, S.Deparment Res Dev & Educ, Halmstad, Sweden,Region Halland (författare)
  • Andersson, T. M.Karolinska Institute,Karolinska Institutet (författare)
  • Eloranta, S.Karolinska Institute,Karolinska Institutet (författare)
  • Smedby, K. E. (författare)
  • Karolinska InstituteKarolinska Institutet (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:American Journal of Hematology: Wiley93:8, s. 1020-10280361-86091096-8652

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy